Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early immune response to factor VIII exposure in previously untreated severe hemophilia A
NL-OMON33198Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Factor VIII in hemophilia A, sponsored by Amsterdam University Medical Center. Primary endpoints: FVIII-specific memory B-cells, T-cell characteristics and 1 more. Started Jun 2009; status: active, not recruiting.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON33198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33198.